RxDoctor Payments Data

Asha Vali, MD

Adult Medicine · Silver Spring, MDNPI 1629134291

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total. Reporting peaked in 2021 at $204 and has fallen 89.6% since, to $21 in 2024.

$692in general payments, 2019–2025

Across 38 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$191
  • Lilly USA, LLC$144
  • AstraZeneca$66
  • Johnson & Johnson$58
  • Amarin Pharma, Inc.$54
  • Gilead$36
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$692 in reported general payments places this provider in the 70th percentile of 34 adult medicine providers in Maryland.

See all adult medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$70,007
Medicare patients
78
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$25,164
OzempicSemaglutide14$16,245
EliquisApixaban12$6,553
QuviviqDaridorexant Hcl12$5,860
Atorvastatin Calcium78$846
Levothyroxine Sodium49$652
Rosuvastatin Calcium20$455
Losartan Potassium45$448
Metoprolol Succinate39$444
Zolpidem Tartrate28$356
Famotidine16$354
Montelukast Sodium18$337
Tramadol Hcl17$327
Metformin Hcl59$293
Gabapentin22$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$16,24514 claims
PfizerEliquis$25$6,55312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 34 adult medicine providers in Maryland.

Other adult medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →